Boceprevir

UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients

(2012) P. Ramachandran et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C

(2012) Calogero Cammà et al.   HEPATOLOGY

Challenges and opportunities for hepatitis C drug development in HIV–hepatitis C virus-co-infected patients

(2011) Vincent Soriano et al.   AIDS

Boceprevir (Victrelis) for HCV: V is for victory and very complex

(2011) Michael Charlton et al.   HEPATOLOGY

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

(2011) Marc G. Ghany et al.   HEPATOLOGY

EASL Clinical Practice Guidelines: Management of hepatitis C virus infection

(2011)   JOURNAL OF HEPATOLOGY

Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b

(2011) J. Vermehren et al.   JOURNAL OF VIRAL HEPATITIS

Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?

(2011) Mitchell L. Shiffman et al.   LIVER INTERNATIONAL

A New Era of Hepatitis C Therapy Begins

(2011) Donald M. Jensen   NEW ENGLAND JOURNAL OF MEDICINE

Coinfection with Human Immunodeficiency Virus and Hepatitis C Virus: Challenges and Therapeutic Advances Insights from the Society of Infectious Diseases Pharmacists

(2011) Paulina Deming et al.   PHARMACOTHERAPY

Characterization of Human Liver Enzymes Involved in the Biotransformation of Boceprevir, a Hepatitis C Virus Protease Inhibitor

(2010) A. Ghosal et al.   DRUG METABOLISM AND DISPOSITION

2016 LONG-TERM OUTCOMES FOLLOWING COMBINATION TREATMENT WITH BOCEPREVIR PLUS PEG-INTRON/RIBAVIRIN (P/R) IN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1 (CHC-G1)

(2010) J.M. Vierling et al.   JOURNAL OF HEPATOLOGY

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

(2010) Paul Y Kwo et al.   LANCET

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

(2009) Simone Susser et al.   HEPATOLOGY

12 DETECTION OF RESISTANT VARIANTS IN THE HEPATITIS C VIRUS NS3 PROTEASE GENE BY CLONAL SEQUENCING AT LONG-TERM FOLLOW-UP IN PATIENTS TREATED WITH BOCEPREVIR

(2009) S. Susser et al.   JOURNAL OF HEPATOLOGY

Diagnosis, management, and treatment of hepatitis C: An update

(2008) Marc G. Ghany et al.   HEPATOLOGY

65 CLONAL ANALYSIS OF MUTATIONS SELECTED IN THE HCV NS3 PROTEASE DOMAIN OF GENOTYPE 1 NON-RESPONDERS TREATED WITH BOCEPREVIR (SCH503034)

(2008) S. Susser et al.   JOURNAL OF HEPATOLOGY

Natural Prevalence of Hepatitis C Virus Variants with Decreased Sensitivity to NS3·4A Protease Inhibitors in Treatment‐Naive Subjects

(2008) Doug J. Bartels et al.   JOURNAL OF INFECTIOUS DISEASES